文献速递乳腺癌

乳腺癌诊断后进入生存期的遗传咨询、检测及与家属沟通

Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
PubMed 文献 · J Clin Oncol · 2024-07-15

基于SEER登记处1412例早期乳腺癌女性,诊断后约7个月和6年调查遗传咨询、检测及与亲属沟通结果。47.4%在任何时点有检测指征,基线有指征者71.9%接受检测,仅随访时有指征者53.3%,无指征者35.0%(P<.001);携带致病性变异者更常与一级成年亲属沟通检测(62.7% vs 38.8%和38.0%,P<.001)。

要点

  • 47.4%的女性在任何时点有遗传检测指征,基线有指征者检测率71.9%。
  • 仅3.4%的生存者进行了直接面向消费者的癌症基因检测。
  • 携带致病性变异者与多数或全部一级成年亲属沟通检测的比例为62.7%,高于意义不明变异者的38.8%和阴性者的38.0%(P<.001)。

核心结论

  • 许多进入生存期有遗传咨询和检测指征的女性并未接受这些服务,但接受检测者会基于结果的临床相关性联系家属。
  • 极少数患者进行直接面向消费者的基因检测,提示这些检测不能替代乳腺癌生存者的临床检测。

研究设计与样本

  • 2014-2015年在佐治亚州和洛杉矶县SEER登记处报告的20-79岁早期乳腺癌女性,于诊断后约7个月和6年接受调查(n=1,412)。
  • 调查内容包括遗传咨询、检测及与亲属沟通结果,并根据诊断时和随访调查时的临床指南将女性分类为有检测指征。

主要发现

  • 47.4%在任何时点有遗传检测指征:28.0%在基线有指征,另19.4%仅在随访调查时有指征。
  • 基线有指征者中71.9%(95%CI 67.4-76.4)报告接受遗传检测,仅随访时有指征者为53.3%(95%CI 47.3-59.2),无指征者为35.0%(95%CI 31.6-38.4)(P<.001)。
  • 控制年龄和临床指征后,接受检测方面无显著种族或族裔差异(P=.239),遗传咨询结果类似。
  • 仅3.4%的生存者进行了直接面向消费者的癌症基因检测。
  • 报告致病性变异的受检者(n=62)与多数或全部一级成年亲属谈论遗传检测的比例为62.7%,高于意义不明变异者(n=49)的38.8%和阴性结果者(n=419)的38.0%(P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine receipt of genetic testing and communication with relatives about results into survivorship after diagnosis of breast cancer. METHODS: Women age 20-79 years diagnosed with early-stage breast cancer in 2014-2015 and reported to the Georgia and Los Angeles County SEER registries were surveyed approximately 7 months and 6 years after diagnosis (n = 1,412). We asked about genetic counseling, testing, and communication with relatives about results. We categorized women into indications for testing on the basis of clinical guidelines at the time of diagnosis and at the time of the follow-up survey (FUPs). RESULTS: A total of 47.4% had indications for genetic testing at any time: 28.0% at baseline and an additional 19.4% at the time of the FUPs (only); 71.9% (95% CI, 67.4 to 76.4) of those with a baseline indication reported genetic testing versus 53.3% (95% CI, 47.3 to 59.2) with an indication at FUPs only and 35.0% (95% CI, 31.6 to 38.4) with no indication (P < .001). There were no significant racial or ethnic differences in receipt of testing, controlling for age and clinical indications (P = .239); results for genetic counseling were similar. Only 3.4% of survivors had direct-to-consumer genetic testing (DTCt) for cancer. Testers who reported a pathogenic variant (n = 62) were much more likely to have talked to most or all their first-degree adult relatives about genetic testing than those with a variant of unknown significance (n = 49) or a negative finding (n = 419): 62.7% versus 38.8% and 38.0%, respectively (P < .001). CONCLUSION: Many women with indications for genetic counseling and testing into survivorship do not receive it. But those tested reach out to family members on the basis of the clinical relevance of their results. Very few patients obtained DTCt, which suggests that these tests do not substitute for clinical testing in breast cancer survivors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Katz SJ, Abrahamse P, Furgal A, et al. Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer. J Clin Oncol. 2024. PMID: 39008790. doi:10.1200/JCO.24.00122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。